Bifidobacterium and the Immune System: A Key Player Against Gastrointestinal Cancers

Abstract

: Gastrointestinal (GI) cancers pose a significant global health challenge, with rising incidence and mortality rates. Recent studies suggest that gut microbiota, particularly Bifidobacterium, plays a crucial role in modulating immune responses and influencing cancer progression. Understanding how Bifidobacterium interacts with the immune system may offer novel therapeutic strategies. A comprehensive review of recent literature was conducted, focusing on the role of Bifidobacterium in defending against GI cancers. The findings indicate that Bifidobacterium enhances the immune response by promoting regulatory T-cell activity and modulating cytokine production. Specific strains of Bifidobacterium have been shown to induce apoptosis in cancer cells and improve the effectiveness of immunotherapy and chemotherapy. Moreover, alterations in gut microbiota composition, particularly the presence of Bifidobacterium, are associated with reduced tumor growth and improved patient outcomes in various cancer models. In conclusion, Bifidobacterium emerges as a promising candidate for therapeutic interventions in GI cancers, with the potential to enhance immune responses and treatment efficacy. However, further research is needed to elucidate its specific mechanisms of action and to optimize the use of Bifidobacterium strains in clinical settings. Future studies should focus on personalized approaches and the integration of Bifidobacterium into existing cancer treatment protocols to improve patient outcomes.